UK must continue to play a part in European medical bodies
Welsh patients could have to wait longer for access to the latest medicines as a result of a hard Brexit, Plaid Cymru has warned.
The party’s Shadow Cabinet Secretary for External Affairs Steffan Lewis warned that leaving bodies such as the European Medical Agency and the European Centre for Disease Prevention and Control will also mean less medical research will happen in the UK, and that the UK will not be privy to the latest information about disease prevention and control.
Plaid Cymru Shadow Cabinet Secretary for External Affairs Steffan Lewis said:
“It’s crucial that we explore ways of maintaining our membership of European medical bodies after Brexit. The UK’s current membership of the European Medical Agency means that hundreds of clinical trials are held in the UK every year, including trials into the use of radiotherapy which is currently being carried out in Velindre, and a trial into the use of local anaesthetic by Aneurin Bevan Health Board.
“If we lose access to the EMA and other bodies such as the European Centre for Disease Prevention and Control, this would mean that we no longer receive the latest information about disease control, we will have less access to medical trials and research, and that drug companies are less likely to try to register their drugs in the UK when a bigger market exists in the EU.
“We need to consider how we overcome these problems to ensure that patients in Wales will continue have the same access to new medical treatment as they do now. This may mean establishing sister organisations affiliated with the EMA and ECDPC so that we can continue to co-operate, and it means that we need to invest in our universities’ research capacity so that we can continue to play a full part in research and development.”
Plaid Cymru Shadow Cabinet Secretary for Public Health Dai Lloyd AM said:
“We are only beginning to fully understand the implication that leaving the EU will have on our NHS. We know that we are likely to lose medical staff because of the uncertainty caused by Brexit, and now we see that we will have to wait longer for access to new medicines and be involved in less medical research.
“It’s crucial that we retain our links, so that patients in Wales will not miss out.”